{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:15:32Z","timestamp":1788570932169,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016694","name":"Science and Technology Development Plan of Shandong Province","doi-asserted-by":"publisher","award":["M-2023050"],"award-info":[{"award-number":["M-2023050"]}],"id":[{"id":"10.13039\/100016694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178103","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:55:32Z","timestamp":1756450532000},"page":"178103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Analysis of differences in dupilumab-associated adverse drug event signals between children and adults based on the FAERS database"],"prefix":"10.1016","volume":"1005","author":[{"given":"Jing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8534-3990","authenticated-orcid":false,"given":"Xiaojin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejphar.2025.178103_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178103_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.spen.2010.10.002","article-title":"Developmental pharmacokinetics","volume":"17","author":"Anderson","year":"2010","journal-title":"Semin. Pediatr. Neurol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178103_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/bjd\/ljae344","article-title":"An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024","volume":"191","author":"Ardern-Jones","year":"2024","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178103_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10086","key":"10.1016\/j.ejphar.2025.178103_bib5","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejphar.2025.178103_bib6","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamadermatol.2023.3849","article-title":"Dupilumab-associated lymphoid reactions in patients with atopic dermatitis","volume":"159","author":"Boesjes","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ejphar.2025.178103_bib7","article-title":"Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy","author":"Cabrera-Perez","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178103_bib8","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","article-title":"Dupilumab safety and efficacy in a phase III open-label extension trial in children 6-11 years of age with severe atopic dermatitis","volume":"13","author":"Cork","year":"2023","journal-title":"Dermatol. Ther."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178103_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/cpt.677","article-title":"Adverse drug reactions in children: the double-edged sword of therapeutics","volume":"101","author":"Elzagallaai","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178103_bib11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jaad.2021.04.045","article-title":"Treatment of patients with atopic dermatitis with weekly dupilumab dosing: a single institutional retrospective medical record review and survey","volume":"86","author":"Gao","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178103_bib12","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1038\/s41598-025-92330-z","article-title":"Analysis and mining of dupilumab adverse events based on FAERS database","volume":"15","author":"Gao","year":"2025","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178103_bib13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and opportunities in accessing and analysing FAERS data: a call towards a collaborative approach","volume":"46","author":"Giunchi","year":"2023","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178103_bib14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178103_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of brexpiprazole: Real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178103_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjd.18565","article-title":"Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials","volume":"183","author":"Katoh","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178103_bib17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178103_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jid.2024.06.1272","article-title":"Cutaneous T-Cell lymphoma after dupilumab use: a Real- world pharmacovigilance study of the FDA adverse event reporting system","volume":"145","author":"Lavin","year":"2025","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2025.178103_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132305","article-title":"Safety evaluation of bempedoic acid: a pharmacovigilance analysis using FDA adverse event reporting system data","volume":"412","author":"Li","year":"2024","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178103_bib20","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1111\/jdv.20279","article-title":"Interactions between dupilumab and vitiligo: a scoping review","volume":"39","author":"Mehta","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178103_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: a review of present indications and off-label uses","volume":"32","author":"Mu\u00f1oz-Bellido","year":"2022","journal-title":"J Investig. Allergol. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178103_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40264-015-0265-0","article-title":"Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems","volume":"38","author":"Osokogu","year":"2015","journal-title":"Drug Saf."},{"issue":"10356","key":"10.1016\/j.ejphar.2025.178103_bib23","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejphar.2025.178103_bib24","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/jdv.19132","article-title":"Vitiligo induced by dupilumab treatment: a case series","volume":"37","author":"Ren","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178103_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ejphar.2025.178103_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455050","article-title":"Biologic drugs induced vitiligo: case reports and review of literature","volume":"15","author":"Shao","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178103_bib27","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178103_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/11587540-000000000-00000","article-title":"Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase","volume":"34","author":"Star","year":"2011","journal-title":"Drug Saf."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178103_bib29","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.545","article-title":"Rapid enlargement of Vitiligo vulgaris after initiation of dupilumab for atopic dermatitis: a case report","volume":"101","author":"Takeoka","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ejphar.2025.178103_bib30","unstructured":"U. S.Food and Drug Administration, 2024a. FDA approves additional maintenance therapy for uncontrolled chronic sinusitis with nasal polyps in children aged 12 and above. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-dupilumab-chronic-sinusitis-nasal-polyps-children-aged-12-years-and-older-06032024. (Accessed 15 July 2024)."},{"key":"10.1016\/j.ejphar.2025.178103_bib31","unstructured":"U.S.Food and Drug Administration, 2024b. FDA approves dupilumab for eosinophilic esophagitis in children aged 1 year and above. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-dupilumab-eosinophilic-esophagitis-children-aged-1-year-and-older. (Accessed 25 January 2024)."},{"key":"10.1016\/j.ejphar.2025.178103_bib32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jad.2024.07.034","article-title":"Clinical safety of daridorexant in insomnia treatment: analysis of FDA adverse event reports","volume":"362","author":"Wang","year":"2024","journal-title":"J. Affect. Disord."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500857X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500857X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:44:12Z","timestamp":1772826252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992500857X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"alternative-id":["S001429992500857X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178103","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of differences in dupilumab-associated adverse drug event signals between children and adults based on the FAERS database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178103"}}